| Human immunodeficiency virus I infection
Genvoya vs Odefsey
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Genvoya vs Odefsey with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOdefsey has a higher rate of injection site reactions vs Genvoya based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Odefsey but not Genvoya, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Genvoya
Odefsey
At A Glance
Oral
Once daily
Fixed-dose combination: INSTI + CYP3A inhibitor + NRTIs
Oral
Once daily
NRTI + NNRTI combination
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet (150 mg EVG, 150 mg COBI, 200 mg FTC, 10 mg TAF) orally once daily with food in patients weighing at least 25 kg with creatinine clearance >=30 mL/min, or adults with creatinine clearance <15 mL/min receiving chronic hemodialysis (administer after hemodialysis on dialysis days).
Human immunodeficiency virus I infection One tablet (emtricitabine 200 mg, rilpivirine 25 mg, tenofovir alafenamide 25 mg) orally once daily with a meal
Contraindications
- Alfuzosin
- Carbamazepine
- Phenobarbital
- Phenytoin
- Rifampin
- Lurasidone
- Pimozide
- Dihydroergotamine
- Ergotamine
- Methylergonovine
- St. John's wort
- Lomitapide
- Lovastatin
- Simvastatin
- Sildenafil for pulmonary arterial hypertension
- Triazolam
- Orally administered midazolam
- Coadministration with carbamazepine
- Coadministration with oxcarbazepine
- Coadministration with phenobarbital
- Coadministration with phenytoin
- Coadministration with rifampin
- Coadministration with rifapentine
- Coadministration with dexamethasone (more than a single dose)
- Coadministration with St. John's wort
- Coadministration with proton pump inhibitors
Adverse Reactions
Most common (>=5%) Nausea, diarrhea, headache, fatigue
Serious Severe acute exacerbations of hepatitis B, immune reconstitution syndrome, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Angioedema, urticaria, rash, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome
Most common (>=2%) Headache, sleep disturbances
Serious Severe acute exacerbations of hepatitis B, skin and hypersensitivity reactions, hepatotoxicity, depressive disorders, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis, immune reconstitution syndrome
Postmarketing Weight increased, severe skin and hypersensitivity reactions including DRESS, nephrotic syndrome, angioedema, urticaria, rash, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome
Pharmacology
GENVOYA is a fixed-dose combination of elvitegravir (an integrase strand transfer inhibitor that prevents HIV-1 DNA integration into host genomic DNA), cobicistat (a CYP3A inhibitor that enhances elvitegravir exposure), emtricitabine (a nucleoside reverse transcriptase inhibitor that causes viral DNA chain termination), and tenofovir alafenamide (a prodrug converted to tenofovir diphosphate, which inhibits reverse transcriptase through DNA chain termination).
Odefsey is a fixed-dose combination of emtricitabine (an NRTI that inhibits HIV-1 reverse transcriptase by chain termination), rilpivirine (an NNRTI that non-competitively inhibits HIV-1 reverse transcriptase), and tenofovir alafenamide (a prodrug that is converted to tenofovir, an NRTI inhibiting HIV-1 reverse transcriptase by chain termination).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Genvoya
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Odefsey
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Genvoya
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Odefsey
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Genvoya
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Odefsey
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GenvoyaView full Genvoya profile
OdefseyView full Odefsey profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.